Boston Biomedical Research Institute Announces A New Alzheimer's Collaboration
Boston Biomedical Research Institute (BBRI) and Neurophage Pharmaceuticals have initiated a joint research program related to Alzheimer's disease. The research will be carried out in the laboratory of Dr. Martin Duennwald at BBRI. Dr. Duennwald, a cell biologist and an expert on protein misfolding and its role in neurodegeneration, will be working with Dr. Rajarman Krishnan from Neurophage, a biophysicist and biochemist, to study changes in the structure of amyloid protein that lead to Alzheimer's disease.
In this collaboration, Boston Biomedical Research Institute seeks to answer questions concerning the underlying principles of protein misfolding and amyloid aggregation, while Neurophage Pharmaceuticals will expand their already extensive, unique platform for drug development to treat early-stage Alzheimer's disease. This joint project should advance basic knowledge on protein folding and lead to significant therapeutic advances.
Results from Outreach
This collaboration is the result of discussions that followed the April 2010 Blout Lecture sponsored by Boston Biomedical Research Institute, featuring Dr. Beka Solomon of Tel Aviv University. The Blout Lecture was established in order to foster collaborations and exchange for the mutual benefit of participating parties. Boston Biomedical Research Institute is pleased to showcase the joint project underway with Neurophage as an example of how the Blout program benefits both science and biotechnology.
About Boston Biomedical Research Institute
Boston Biomedical Research Institute is an independent non-profit institute dedicated to basic biomedical research to promote the understanding, treatment and prevention of specific diseases, and to training research scientists.
Investigators focus on the structure and function of proteins that control cellular communication, muscle contractility, cell movement, growth and differentiation and on the underlying causes of human diseases from the study of disease models in order to drive development of novel therapeutics.
NeuroPhage is a Boston based biotechnology company established in 2006. It is developing a breakthrough protein disaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer's disease (AD) drug candidate, NPT001, safely and effectively disaggregates existing Aβ plaque in preclinical animal models, which is unique among disease-modifying approaches for AD.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.